The business case for vaccine and drug manufacturing in middle-income countries

Lancet Glob Health. 2022 Jul;10(7):e944-e945. doi: 10.1016/S2214-109X(22)00249-2.
No abstract available

Publication types

  • Comment

MeSH terms

  • Commerce
  • Developing Countries*
  • Humans
  • Income
  • Vaccines*

Substances

  • Vaccines